NASDAQ (usa) arrow 6715.56 -12.11 -0.18%
FTSE 100 (london) arrow 7487.96 -5.12 -0.07%
DAX (german) arrow 13465.51 235.94 1.78%
NIKKEI 225 (japan) arrow 22420.08 408.47 1.86%
Hang - Seng (hong kong) arrow 28594.06 348.52 1.23%
NIFTY - 50 (india)
Straits Times (singapore) arrow 3391.61 17.53 0.52%
KOSPI (korea) arrow 2556.47 33.04 1.31%
All Ordinaries (australia) arrow 6005.30 28.90 0.48%
BOVESPA (brazil) arrow 74092.76 -215.73 -0.29%

Novo Nordisk A/S (CO: NOVO-B)

 
NOVO-B Technical Analysis
5
As on 17th Nov 2025 NOVO-B STOCK Price closed @ 312.70 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 738.82 & Strong Sell for SHORT-TERM with Stoploss of 944.12 we also expect STOCK to react on Following IMPORTANT LEVELS.
 
 

NOVO-BSTOCK Price

Open 312.05 Change Price %
High 312.85 1 Day 1.65 0.53
Low 303.65 1 Week 5.75 1.87
Close 312.70 1 Month -73.85 -19.10
Volume 4402457 1 Year -660.60 -67.87
52 Week High 1028.00 | 52 Week Low 289.50
 
CO Denmark Most Active Stocks
SAS 0.01 0.00%
NOVO-B 312.70 0.53%
CONFRZ 0.02 0.00%
ORSTED 131.00 5.69%
VWS 155.70 0.06%
ALMB 18.21 0.83%
GREENH 0.41 -6.82%
GN 98.80 -3.56%
AMBU-B 85.35 -0.06%
ASTRLS 1.15 8.49%
 
CO Denmark Top Gainers Stocks
HYDRCT 0.60 46.34%
HYPE 3.66 22.00%
STENO 2.72 19.82%
DKIEEU 249.00 15.81%
FASTPC 19.80 14.45%
SAME 1.45 10.69%
SAME 1.45 10.69%
GREENM 81.00 10.05%
GERHSP 67.00 9.84%
ASTRLS 1.15 8.49%
 
CO Denmark Top Losers Stocks
VALUER 0.25 -21.88%
BLVIS-A 0.40 -18.37%
ACT 0.72 -12.20%
ACT 0.72 -12.20%
ACT 0.72 -12.20%
ACT 0.72 -12.20%
ACT 0.72 -12.20%
ACT 0.72 -12.20%
ACT 0.72 -12.20%
ACT 0.72 -12.20%
 
 
NOVO-B
Daily Charts
NOVO-B
Intraday Charts
Whats New @
Bazaartrend
NOVO-B
Free Analysis
 
NOVO-B Important Levels Intraday
RESISTANCE330.43
RESISTANCE324.74
RESISTANCE321.23
RESISTANCE317.71
SUPPORT307.69
SUPPORT304.17
SUPPORT300.66
SUPPORT294.97
 
NOVO-B Forecast November 2025
4th UP Forecast712.17
3rd UP Forecast584.06
2nd UP Forecast504.87
1st UP Forecast425.68
1st DOWN Forecast199.72
2nd DOWN Forecast120.53
3rd DOWN Forecast41.34
4th DOWN Forecast-86.77
 
NOVO-B Weekly Forecast
4th UP Forecast367.43
3rd UP Forecast349.88
2nd UP Forecast339.03
1st UP Forecast328.18
1st DOWN Forecast297.22
2nd DOWN Forecast286.37
3rd DOWN Forecast275.52
4th DOWN Forecast257.97
 
NOVO-B Forecast2025
4th UP Forecast1749.47
3rd UP Forecast1288.69
2nd UP Forecast1003.87
1st UP Forecast719.05
1st DOWN Forecast-93.65
2nd DOWN Forecast-378.47
3rd DOWN Forecast-663.29
4th DOWN Forecast-1124.07
 
 
NOVO-B Other Details
Segment EQ
Market Capital 1565371138048.00
Sector Healthcare
Industry Biotechnology
Offical website >
 
NOVO-B Address
NOVO-B
 
NOVO-B Latest News
 
Your Comments and Response on Novo Nordisk A/S
 
NOVO-B Business Profile
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark. Address: Novo Allé 1, Bagsvaerd, Denmark, 2880
 
© 2005-2023 BazaarTrend.com All rights reserved.

Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service